Albiger N M, Regazzo D, Rubin B, Ferrara A M, Rizzati S, Taschin E, Ceccato F, Arnaldi G, Pecori Giraldi F, Stigliano A, Cerquetti L, Grimaldi F, De Menis E, Boscaro M, Iacobone M, Occhi G, Scaroni C
Endocrinology Unit, Department of Medicine DIMED, Padova University Hospital, Padua, Italy.
Familial Cancer Clinic and Oncoendocrinology, Veneto Institute of Oncology, IRCCS, Padua, Italy.
Endocrine. 2017 Mar;55(3):959-968. doi: 10.1007/s12020-016-0956-z. Epub 2016 Apr 19.
ARMC5 mutations have recently been identified as a common genetic cause of primary bilateral macronodular adrenal hyperplasia (PBMAH). We aimed to assess the prevalence of ARMC5 germline mutations and correlate genotype with phenotype in a large cohort of PBMAH patients. A multicenter study was performed, collecting patients from different endocrinology units in Italy. Seventy-one PBMAH patients were screened for small mutations and large rearrangements in the ARMC5 gene: 53 were cortisol-secreting (two with a family history of adrenal hyperplasia) and 18 were non-secreting cases of PBMAH. Non-mutated and mutated patients' clinical phenotypes were compared and related to the type of mutation. A likely causative germline ARMC5 mutation was only identified in cortisol-secreting PBMAH patients (one with a family history of adrenal hyperplasia and ten apparently sporadic cases). Screening in eight first-degree relatives of three index cases revealed four carriers of an ARMC5 mutation. Evidence of a second hit at somatic level was identified in five nodules. Mutated patients had higher cortisol levels (p = 0.062), and more severe hypertension and diabetes (p < 0.05). Adrenal glands were significantly larger, with a multinodular phenotype, in the mutant group (p < 0.01). No correlation emerged between type of mutation and clinical parameters. ARMC5 mutations are frequent in cortisol-secreting PBMAH and seem to be associated with a particular pattern of the adrenal masses. Their identification may have implications for the clinical care of PBMAH cases and their relatives.
ARMC5突变最近被确定为原发性双侧大结节性肾上腺增生(PBMAH)的常见遗传原因。我们旨在评估ARMC5种系突变的患病率,并在一大群PBMAH患者中使基因型与表型相关联。开展了一项多中心研究,从意大利不同的内分泌科收集患者。对71例PBMAH患者进行了ARMC5基因小突变和大重排的筛查:53例为分泌皮质醇型(其中2例有肾上腺增生家族史),18例为非分泌型PBMAH病例。比较了未突变和突变患者的临床表型,并将其与突变类型相关联。仅在分泌皮质醇的PBMAH患者中鉴定出可能的致病种系ARMC5突变(1例有肾上腺增生家族史,10例显然为散发病例)。对3例索引病例的8名一级亲属进行筛查,发现4名ARMC5突变携带者。在5个结节中发现了体细胞水平二次打击的证据。突变患者的皮质醇水平较高(p = 0.062),高血压和糖尿病更严重(p < 0.05)。突变组的肾上腺明显更大,具有多结节表型(p < 0.01)。突变类型与临床参数之间未发现相关性。ARMC5突变在分泌皮质醇的PBMAH中很常见,似乎与肾上腺肿块的特定模式有关。其鉴定可能对PBMAH病例及其亲属的临床护理有影响。